// App-Quantinova.ai

CT201 : Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)

Researchers

Presenter

  • Byoung Chul Cho

Principal Investigators

  • Johanna Bendell

  • Enriqueta Felip

  • Melissa Johnson

  • Yoon-Koo Kang

  • Farah Louise Lim

  • Teresa Macarulla

  • Gulam Manji

  • Do-Youn Oh

  • Osama Rahma

  • Simon Allen

  • Edward Cha

  • Denise Cotting

  • Hans-Joachim Helms

  • Jan Pintoffl

  • Pakeeza Sayyed

  • Xiaosong Zhang

  • Kyu-pyo Kim

Medical Centers

  • Yonsei University Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Columbia University Medical Center, New York, NY

  • Seoul National University College of Medicine, Seoul, Korea

  • Dana-Farber Cancer Institute, Boston, MA

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

Locations

  • Republic of South Korea

  • United States

  • Spain

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Non Small Cell Lung cancer

  • Small cell lung cancer

  • Gastric Cancer

  • Lung Cancer

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Atezolizumab

  • Gemcitabine

  • Cobimetinib

  • Paclitaxel

  • Docetaxel

  • mFOLFOX6

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • I

Study Id's

  • NCT03337698

  • NCT03193190

  • NCT03281369

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved